116 related articles for article (PubMed ID: 22297111)
21. Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.
Esbenshade TA; Yao BB; Witte DG; Carr TL; Sharma R; Baranowski JL; Krueger KM; Miller TR; Surber BW; Faghih R; Hancock AA
Inflamm Res; 2005 Apr; 54 Suppl 1():S46-7. PubMed ID: 15928830
[No Abstract] [Full Text] [Related]
22. Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
Nagase T; Mizutani T; Sekino E; Ishikawa S; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Sato N
J Med Chem; 2008 Nov; 51(21):6889-901. PubMed ID: 18841880
[TBL] [Abstract][Full Text] [Related]
23. From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Dunn D; Raddatz R; Ator MA; Bacon ER; Chatterjee S
Chem Biol Drug Des; 2013 Mar; 81(3):433-5. PubMed ID: 23205610
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.
Becknell NC; Lyons JA; Aimone LD; Huang Z; Gruner JA; Raddatz R; Hudkins RL
Bioorg Med Chem; 2012 Jun; 20(12):3880-6. PubMed ID: 22578490
[TBL] [Abstract][Full Text] [Related]
25. A new family of H3 receptor antagonists based on the natural product Conessine.
Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Sengupta D; Duffield JJ; Semple G; Webb RR; Sage C; Ren A; Pereira G; Knudsen J; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Whelan K; Grottick AJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1490-4. PubMed ID: 18194865
[TBL] [Abstract][Full Text] [Related]
26. Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.
Dvorak CA; Apodaca R; Xiao W; Jablonowski JA; Bonaventure P; Dugovic C; Shelton J; Lord B; Miller K; Dvorak LK; Lovenberg TW; Carruthers NI
Eur J Med Chem; 2009 Oct; 44(10):4098-106. PubMed ID: 19524331
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.
Ishikawa M; Furuuchi T; Yamauchi M; Yokoyama F; Kakui N; Sato Y
Bioorg Med Chem; 2010 Jul; 18(14):5441-8. PubMed ID: 20541426
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists.
Josef KA; Aimone LD; Lyons J; Raddatz R; Hudkins RL
Bioorg Med Chem Lett; 2012 Jun; 22(12):4198-202. PubMed ID: 22617490
[TBL] [Abstract][Full Text] [Related]
29. A Novel Potent and Selective Histamine H
Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
[TBL] [Abstract][Full Text] [Related]
30. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
[TBL] [Abstract][Full Text] [Related]
31. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.
Pelloux-Léon N; Fkyerat A; Piripitsi A; Tertiuk W; Schunack W; Stark H; Garbarg M; Ligneau X; Arrang JM; Schwartz JC; Ganellin CR
J Med Chem; 2004 Jun; 47(12):3264-74. PubMed ID: 15163206
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
[TBL] [Abstract][Full Text] [Related]
33. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
34. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
[No Abstract] [Full Text] [Related]
35. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
36. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Gbahou F; Davenas E; Morisset S; Arrang JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
[TBL] [Abstract][Full Text] [Related]
37. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
[TBL] [Abstract][Full Text] [Related]
38. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
39. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
[TBL] [Abstract][Full Text] [Related]
40. Constitutive activity of the histamine H3 receptor.
Arrang JM; Morisset S; Gbahou F
Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
